Bressler NM, Veith M, Hamouz J, Ernest J, et al. Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes. Br J Ophthalmol 2021 Oct 16. pii: bjophthalmol-2021-319637.
PMID: 34656987